Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Unilabs and Diagnoplex SA Announce the Swiss Market Launch of Colox

Published: Saturday, March 01, 2014
Last Updated: Saturday, March 01, 2014
Bookmark and Share
A non-invasive colon cancer screening test.

Unilabs and Diagnoplex SA have announced the Swiss market launch of Colox®, a non-invasive screening test for colorectal cancer.

Colox® is offered as a service by Unilabs’ clinical diagnostic service laboratories in Switzerland. Additional countries within Unilabs’ network of laboratories are planned to follow in 2014.

The novel Colox® test can detect colorectal cancer from a routine blood sample through all stages of disease, with a particular focus on early stages, where the prognosis is optimal. The test is based on quantifying a unique 29 biomarker molecular signature using quantitative RT-PCR.

The effectiveness of Colox® was confirmed in a series of prospective clinical studies. Colorectal cancer screening guidelines indicate that women and men at average risk should be offered screening for colorectal cancer and adenomatous polyps beginning at age 50 years.

‘We are proud to offer this important new option to efficiently screen for colorectal cancer, the second most important cancer in terms of mortality in developed countries’ comments Stavros Therianos, CEO of Diagnoplex SA and adds ‘our goal is now to make the test available to as many individuals at risk as possible. In parallel with this robust commercialization effort, we are looking to raise the additional funds necessary to perform complementary clinical studies leading to a full reimbursement of Colox®. To this end, we are open to discussion with interested parties’.

Alain Cahen, Unilabs’ Managing Director in Switzerland, said: ‘It is a great success to announce that Colox® is now produced by Unilabs. We have prepared a distribution strategy and a communication campaign that will reach doctors as of March. This campaign will include information regarding the logistics and availability of Colox® in the different regions of Switzerland, including explanatory brochures for the doctors and for the individuals at risk’.

Thierry Mauvernay, Delegate of the Board of Debiopharm Group - a lead investor in Diagnoplex - agreed, adding: ‘We believe that the Colox® test offers a much better and easier solution for patients than existing alternatives. As such we believe that the availability of Colox® will help increase the early detection of this important cancer, allowing treatment at an earlier stage where there is a much better chance of success’.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!